Capricor Therapeutics (CAPR) Notes Payables (2013 - 2021)

Capricor Therapeutics (CAPR) posted quarterly Notes Payables of $282691.0 for Q1 2021, up 14.59% quarter-over-quarter from $246689.0 in Q4 2020.

Capricor Therapeutics (CAPR) Notes Payables (2013 - 2021) Analysis & Trends

Capricor Therapeutics' Notes Payables history runs 3 years deep, the most recent figure standing at $282691.0 for Q1 2021.

In Q1 2021, Notes Payables changed N/A year-over-year to $282691.0; the TTM figure through Mar 2021 stood at $282691.0 (changed N/A YoY), while the FY2020 annual figure was $246689.0, changed N/A from the prior year.
Notes Payables for Q1 2021 stood at $282691.0, up from $246689.0 in the prior quarter.
The five-year high for Notes Payables was $282691.0 in Q1 2021, with the low at $139927.0 in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Capricor Therapeutics	383.47 Mn	383.47 Mn	-

Download Data